For patients who reached the Medicare Part D coverage gap, discontinuation was more likely for patients taking osteoporosis medication.
John W. Hanna, MBA
Advertisement
Articles by John W. Hanna, MBA
Advertisement
Latest Updated Articles
- Persistence With Biologic Therapies in the Medicare Coverage Gap
Published: November 7th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5
